Washington University’s Clinical Genomics Laboratory processes a variety of tissue specimens for the diagnosis and monitoring of many types of cancer.
We offer chromosome analysis, FISH and FFPE FISH to detect translocations, deletions, duplications, amplifications, and to monitor the status of bone marrow transplants. We correlate the histology with FISH testing utilizing customized as well as standardized probes to assess specific genetic loci that may assist in:
- Diagnosis of disease (e.g. IGH-CCND1, IGH-BCL2)
- Prognosis of disease (e.g. c-MYC, n-MYC, BCR-ABL, 1p/19q)
- Minimal residual disease (e.g. XY chimerism)
- Targetable drug therapy (e.g. EGFR. RET, ROS1, ALK, HER2)
| Summary | Detects aneuploidy, rearrangements, deletions, inversions |
| Specimen types | Bone core, bone marrow aspirate, lymph node, peripheral blood, solid tumor, tissue biopsy |
| Turnaround times | 14-21 days |
| Summary | Detects aneuploidy, rearrangements, deletions and inversions associated with hematologic malignancies |
| Specimen types | Bone core, bone marrow aspirate, lymph node, peripheral blood |
| Specific tests offered | Acute Myeloid Leukemia (CBFB, CEP8, D7S486, EGR1, EVI, MLL, PML/RARA, RARA, RUNX1/RUNX1T1) B-cell Acute Lymphoblastic Leukemia (BCR/ABL, CDKN2A, CEP4/10/17, ETV6/RUNX1, IGH, MLL, TCF3) T-cell Acute Lymphoblastic Leukemia (CDKN2A, MYC, TCR, TRB) Chronic Lymphocytic Leukemia (ATM, BCL2, BCL6, CCND1/IGH, CEP12, D13S319, MYB, TP53) Chronic Myleogeneous Leukemia/Myeloproliferative Disorder (BCR/ABL1, FIP1L1/PDGFRA) Chronic Myelomonocytic Leukemia (PDGFRB) Myelodysplastic Disorder (CEP8, D7S486, D13S319, D20S108, EGR1, ETV6) Multiple Myeloma (CCND1/IGH, CKS1B/CDKN2C, D13S319, FGFR3/IGH, IGH/MAP, TP53) Lymphoma (BCL6, IGH, MYC) Anaplastic Large Cell Lymphoma (ALK) Burkitt’s Lymphoma (CCND1/IGH, MYC) Diffuse Large Cell Lymphoma (IGH/BCL2) MALT Lymphoma (API1/MALT1, IGH/BCL2, MALT1) Mantle Cell Lymphoma (CCND1/IGH) Small Cell Leukemia-Lymphoma (FGFR1) |
| Turnaround times | 24-72 hours |
| Summary | Detects rearrangements, amplifications and deletions associated with solid tumors and hematologic malignancies |
| Specimen types | FFPE slides derived from solid tumors and tissue biospies |
| Specific tests offered | Breast Cancer (HER2) Lung Cancer (ALK, EGFR, FGFR1, MET, RET, ROS1) Neuropathologic Malignancies (BRAF, CDKN2A, EGFR, HER2, MYC, MYCN, PTEN, 1p/9q, 1p/14q, 22q) Sarcomas (DDIT3, EWSR1, FOXO1, FUS, SS18) Hematologic Malignancies (ALK, BCL6, BCR/ABL, BIRC3/MALT, IGH, IGH/BCL2, IGH/CCND1, MLL, MYC) |
| Turnaround times | 3-5 days |